TB Meningitis in HIV-Positive Patients in Europe and Argentina: Clinical Outcome and Factors Associated with Mortality
Table 2
Multivariate poisson regression models for death in 3 separate TB groups.
TB meningitis
Pulmonary TB
Extrapulmonary TB
aIRR**
95% CI
aIRR
95% CI
aIRR
95% CI
Region
East versus other
5.41
2.58–11.34
<0.0001
2.87
1.62–5.08
0.0003
11.32
7.35–17.44
<0.0001
On cART at TB
Yes versus no
0.25
0.11–0.58
0.0013
0.38
0.17–0.82
0.014
0.38
0.21–0.69
0.0016
Prior AIDS at TB
Yes versus no
4.82
2.61–8.92
<0.0001
0.92
0.57 – 1.49
0.74
1.55
1.07–2.25
0.022
Multidrug resistant
Yes versus no
0.30
0.06–1.43
0.13
1.72
0.75–3.94
0.20
0.71
0.22–2.29
0.57
Rifamycin in initial regimen
Yes versus no
1.18
0.62–2.23
0.62
0.81
0.48–1.35
0.42
0.85
0.61–1.18
0.32
Disseminated
Yes versus no
2.12
0.88–5.13
0.095
*
*
*
1.42
0.83–2.42
0.20
CD4 at TB
≤200 cells/mm3
1.00
0.52–1.92
0.99
1.99
1.15–3.43
0.014
2.40
1.65–3.50
<0.0001
>200 cells/mm3
1.00
—
—
1.00
—
—
1.00
—
—
Unknown
0.54
0.23–1.20
0.17
1.27
0.78–2.08
0.34
1.90
1.27–2.84
0.0019
Age
Per 10 yr older
0.81
0.60–1.10
0.18
0.89
0.68–1.15
0.37
1.07
0.90–1.27
0.24
Diagnosis
Definitive versus presumptive/probable
1.33
0.74–2.37
0.34
0.86
0.54–1.37
0.53
0.72
0.53–0.97
0.033
No patients with disseminated disease in pulmonary TB group.
**The adjusted incidence rate ratios (aIRRs) were adjusted for all other variables in the model. Tests for interaction: TB type *region (), TB type *on cART at TB (), TB type *AIDS (), TB type *MDR (), TB type *rifamycin in regimen (), TB type *CD4 (), TB type *age (), TB type *diagnosis type (), and TB type *disseminated disease ().